Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Khayat-Khoei M, Bhattacharyya S, Katz J, Harrison D, Tauhid S, Bruso P, Houtchens MK, Edwards KR, Bakshi R. COVID-19 mRNA vaccination leading to CNS inflammation: a case series. J Neurol 2021. [PMID: 34480607 DOI: 10.1007/s00415-021-10780-7] [Citation(s) in RCA: 83] [Impact Index Per Article: 20.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Revised: 08/26/2021] [Accepted: 08/26/2021] [Indexed: 01/08/2023]

For:	Khayat-Khoei M, Bhattacharyya S, Katz J, Harrison D, Tauhid S, Bruso P, Houtchens MK, Edwards KR, Bakshi R. COVID-19 mRNA vaccination leading to CNS inflammation: a case series. J Neurol 2021. [PMID: 34480607 DOI: 10.1007/s00415-021-10780-7] [Citation(s) in RCA: 83] [Impact Index Per Article: 20.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Revised: 08/26/2021] [Accepted: 08/26/2021] [Indexed: 01/08/2023]

Number

Cited by Other Article(s)

Justiz-Vaillant A, Roopnarine K, Solomon S, Phillips A, Sandy S, Subero A, Seepersad S, Span N, Ramnath P, Ramnarine A, Ramdath B, Rampaul C, Ramdial R, Phagoo D, Ramdhanie T, Moonilal V, Poliah EM, Poonwassie S, Punilal K, Panchoo S, Parris J, Oudit S, Muir T, Nicholas-Joseph J, Pandit BR, Pakeerah S, Sookoo V, Richards P, John T, Gopaul D, Soodeen S, Arozarena-Barbosa O, Williams A, Unakal C, Fundora RA, Thompson R, Akpaka PE. COVID-19 Vaccines Effectiveness and Safety in Trinidad and Tobago: A Systematic Review and Meta-Analysis. Microorganisms 2025;13:135. [PMID: 39858903 PMCID: PMC11767614 DOI: 10.3390/microorganisms13010135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2024] [Revised: 12/03/2024] [Accepted: 01/07/2025] [Indexed: 01/27/2025] Open

Affiliation(s)

Angel Justiz-Vaillant Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Kimberly Roopnarine Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Shaundell Solomon Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Alyssa Phillips Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Solange Sandy Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Alyssa Subero Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Sarah Seepersad Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Nicholas Span Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Phalmanie Ramnath Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Akaasha Ramnarine Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Bimala Ramdath Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Chelsea Rampaul Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Renissa Ramdial Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Dana Phagoo Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Thalia Ramdhanie Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Vinaya Moonilal Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Emily-Marie Poliah Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Steffan Poonwassie Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Karishta Punilal Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Sarah Panchoo Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Justice Parris Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Steven Oudit Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Trudy Muir Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Johnson Nicholas-Joseph Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Bijey Raj Pandit Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Sanjeev Pakeerah Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Vesham Sookoo Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Patrice Richards Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Tishia John Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Darren Gopaul Department of Surgery, Morehouse School of Medicine, Atlanta, GA 30310, USA;
Sachin Soodeen Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Odette Arozarena-Barbosa Eric Williams Medical Sciences Complex, North Central Regional Health Authority, Champs Fleurs 330912, Trinidad and Tobago (R.A.F.)
Arlene Williams Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Chandrashehkar Unakal Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Rodolfo Arozarena Fundora Eric Williams Medical Sciences Complex, North Central Regional Health Authority, Champs Fleurs 330912, Trinidad and Tobago (R.A.F.) Department of Clinical and Surgical Sciences, Faculty of Medical Sciences, University of the West Indies, St. Augustine 330912, Trinidad and Tobago
Reinand Thompson Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)
Patrick Eberechi Akpaka Department of Para-Clinical Sciences, University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago; (K.R.); (S.S.); (A.P.); (A.S.); (S.S.); (N.S.); (P.R.); (A.R.); (B.R.); (C.R.); (R.R.); (D.P.); (T.R.); (V.M.); (E.-M.P.); (S.P.); (K.P.); (S.P.); (J.P.); (S.O.); (T.M.); (J.N.-J.); (B.R.P.); (S.P.); (V.S.); (P.R.); (T.J.); (S.S.); (A.W.); (C.U.); (R.T.); (P.E.A.)

Collapse

Alonso Castillo R, Martínez Castrillo JC. Neurological manifestations associated with COVID-19 vaccine. Neurologia 2025;40:66-76. [PMID: 36288776 PMCID: PMC9595420 DOI: 10.1016/j.nrleng.2022.09.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Accepted: 09/28/2022] [Indexed: 11/06/2022] Open

Kim HJ, Kim MH, Choi MG, Chun EM. Psychiatric adverse events following COVID-19 vaccination: a population-based cohort study in Seoul, South Korea. Mol Psychiatry 2024;29:3635-3643. [PMID: 38834668 PMCID: PMC11541197 DOI: 10.1038/s41380-024-02627-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/09/2024] [Revised: 05/22/2024] [Accepted: 05/24/2024] [Indexed: 06/06/2024]

Abstract

Evidence has suggested an increased risk of psychiatric manifestations following viral infections including coronavirus disease-2019 (COVID-19). However, psychiatric adverse events (AEs) after COVID-19 vaccination, which were documented in case reports and case series, remain unclear. This study is aimed to investigate the psychiatric AEs after COVID-19 vaccination from a large population-based cohort in Seoul, South Korea. We recruited 50% of the Seoul-resident population randomly selected from the Korean National Health Insurance Service (KNHIS) claims database on 1, January, 2021. The included participants (n = 2,027,353) from the Korean National Health Insurance Service claims database were divided into two groups according to COVID-19 vaccination. The cumulative incidences per 10,000 of psychiatric AEs were assessed on one week, two weeks, one month, and three months after COVID-19 vaccination. Hazard ratios (HRs) and 95% Confidence interval (CIs) of psychiatric AEs were measured for the vaccinated population. The cumulative incidence of depression, anxiety, dissociative, stress-related, and somatoform disorders, sleep disorders, and sexual disorders at three months following COVID-19 vaccination were higher in the vaccination group than no vaccination group. However, schizophrenia and bipolar disorders showed lower cumulative incidence in the vaccination group than in the non-vaccinated group. Depression (HR [95% CI] = 1.683 [1.520-1.863]), anxiety, dissociative, stress-related, and somatoform disorders (HR [95% CI] = 1.439 [1.322-1.568]), and sleep disorders (HR [95% CI] = 1.934 [1.738-2.152]) showed increased risks after COVID-19 vaccination, whereas the risks of schizophrenia (HR [95% CI] = 0.231 [0.164-0.326]) and bipolar disorder (HR [95% CI] = 0.672 [0.470-0.962]). COVID-19 vaccination increased the risks of depression, anxiety, dissociative, stress-related, and somatoform disorders, and sleep disorders while reducing the risk of schizophrenia and bipolar disorder. Therefore, special cautions are necessary for administering additional COVID-19 vaccinations to populations vulnerable to psychiatric AEs.

Collapse

Su MAO, Doquenia MLM, Tanglao MJ, Rosales R. Peripheral Immune-Mediated Neuropathy Before and During the COVID-19 Pandemic: A Retrospective Cross-Sectional Study in a Referral Center. Cureus 2024;16:e74131. [PMID: 39712713 PMCID: PMC11662227 DOI: 10.7759/cureus.74131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/20/2024] [Indexed: 12/24/2024] Open

Karam R, Iskandar K, Watfa M, Zeitoun A. Serious adverse events following immunization with COVID-19 vaccines in Lebanon: a retrospective analysis of the National Pharmacovigilance Database. BMC Public Health 2024;24:2905. [PMID: 39434043 PMCID: PMC11495130 DOI: 10.1186/s12889-024-20297-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2024] [Accepted: 10/04/2024] [Indexed: 10/23/2024] Open

Hollist M, Hollist A, Au K, Betts C, Kirmani M, Kirmani M, Armour B, Udeh MC, Kirmani BF. Multiple Sclerosis and COVID-19: An Overview on Risk, Severity, and Association With Disease Modifying Therapies. Neurosci Insights 2024;19:26331055241265668. [PMID: 39347459 PMCID: PMC11437550 DOI: 10.1177/26331055241265668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2023] [Accepted: 06/04/2024] [Indexed: 10/01/2024] Open

Khatami SS, Revheim ME, Høilund-Carlsen PF, Alavi A, Ghorbani Shirkouhi S, Andalib S. Central nervous system manifestations following vaccination against COVID-19. Brain Behav Immun Health 2024;38:100788. [PMID: 38818372 PMCID: PMC11137405 DOI: 10.1016/j.bbih.2024.100788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2023] [Revised: 03/03/2024] [Accepted: 05/02/2024] [Indexed: 06/01/2024] Open

Hamzavi SS, Bahrololoom R, Saeb S, Marandi NH, Hosseini M, Hesam Abadi AK, Jamalidoust M. Humoral immune response and safety of Sars-Cov-2 vaccine in people with multiple sclerosis. BMC Immunol 2024;25:35. [PMID: 38898409 PMCID: PMC11186195 DOI: 10.1186/s12865-024-00628-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2024] [Accepted: 06/07/2024] [Indexed: 06/21/2024] Open

Lee KW, Yap SF, Amin-Nordin S, Ngeow YF. Cardiac and Neurological Complications Post COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series. Vaccines (Basel) 2024;12:575. [PMID: 38932303 PMCID: PMC11209191 DOI: 10.3390/vaccines12060575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2024] [Revised: 05/14/2024] [Accepted: 05/15/2024] [Indexed: 06/28/2024] Open

Bianco A, Di Sante G, Colò F, De Arcangelis V, Cicia A, Del Giacomo P, De Bonis M, Morganti TG, Carlomagno V, Lucchini M, Minucci A, Calabresi P, Mirabella M. Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant? Int J Mol Sci 2024;25:4556. [PMID: 38674141 PMCID: PMC11050425 DOI: 10.3390/ijms25084556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2024] [Revised: 04/13/2024] [Accepted: 04/18/2024] [Indexed: 04/28/2024] Open

Abstract

A few cases of multiple sclerosis (MS) onset after COVID-19 vaccination have been reported, although the evidence is insufficient to establish causality. The aim of this study is to compare cases of newly diagnosed relapsing-remitting MS before and after the outbreak of the COVID-19 pandemic and the impact of COVID-19 vaccination. Potential environmental and genetic predisposing factors were also investigated, as well as clinical patterns. This is a single-centre retrospective cohort study including all patients who presented with relapsing-remitting MS onset between January 2018 and July 2022. Data on COVID-19 vaccination administration, dose, and type were collected. HLA-DRB1 genotyping was performed in three subgroups. A total of 266 patients received a new diagnosis of relapsing-remitting MS in our centre, 143 before the COVID-19 pandemic (until and including March 2020), and 123 during the COVID-19 era (from April 2020). The mean number of new MS onset cases per year was not different before and during the COVID-19 era and neither were baseline patients' characteristics, type of onset, clinical recovery, or radiological patterns. Fourteen (11.4%) patients who subsequently received a new diagnosis of MS had a history of COVID-19 vaccination within one month before symptoms onset. Patients' characteristics, type of onset, clinical recovery, and radiological patterns did not differ from those of patients with non-vaccine-related new diagnoses of MS. The allele frequencies of HLA-DRB1*15 were 17.6% and 22.2% in patients with non-vaccine-related disease onset before and during the COVID-19 era, respectively, while no case of HLA-DRB1*15 was identified among patients with a new diagnosis of MS post-COVID-19 vaccine. In contrast, HLA-DRB1*08+ or HLA-DRB1*10+ MS patients were present only in this subgroup. Although a causal link between COVID-19 vaccination and relapsing-remitting MS cannot be detected, it is interesting to note and speculate about the peculiarities and heterogeneities underlying disease mechanisms of MS, where the interactions of genetics and the environment could be crucial also for the follow-up and the evaluation of therapeutic options.

Collapse

Affiliation(s)

Assunta Bianco Division of Neurology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy Department of Neurosciences, Centro di Ricerca per la Sclerosi Multipla “Anna Paola Batocchi”, Catholic University of Sacred Heart, 00168 Rome, Italy
Gabriele Di Sante Department of Medicine and Surgery, Section of Human, Clinical and Forensic Anatomy, University of Perugia, 06123 Perugia, Italy
Francesca Colò Department of Neurosciences, Centro di Ricerca per la Sclerosi Multipla “Anna Paola Batocchi”, Catholic University of Sacred Heart, 00168 Rome, Italy
Valeria De Arcangelis Division of Neurology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
Alessandra Cicia Department of Neurosciences, Centro di Ricerca per la Sclerosi Multipla “Anna Paola Batocchi”, Catholic University of Sacred Heart, 00168 Rome, Italy
Paola Del Giacomo Department of Laboratory and Infectious Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
Maria De Bonis Departmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy Genomics Core Facility, Gemelli Science and Technology Park (G-STeP), Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
Tommaso Giuseppe Morganti Department of Neurosciences, Centro di Ricerca per la Sclerosi Multipla “Anna Paola Batocchi”, Catholic University of Sacred Heart, 00168 Rome, Italy
Vincenzo Carlomagno Department of Neurosciences, Centro di Ricerca per la Sclerosi Multipla “Anna Paola Batocchi”, Catholic University of Sacred Heart, 00168 Rome, Italy
Matteo Lucchini Division of Neurology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy Department of Neurosciences, Centro di Ricerca per la Sclerosi Multipla “Anna Paola Batocchi”, Catholic University of Sacred Heart, 00168 Rome, Italy
Angelo Minucci Departmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy Genomics Core Facility, Gemelli Science and Technology Park (G-STeP), Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
Paolo Calabresi Division of Neurology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy Department of Neurosciences, Centro di Ricerca per la Sclerosi Multipla “Anna Paola Batocchi”, Catholic University of Sacred Heart, 00168 Rome, Italy
Massimiliano Mirabella Division of Neurology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy Department of Neurosciences, Centro di Ricerca per la Sclerosi Multipla “Anna Paola Batocchi”, Catholic University of Sacred Heart, 00168 Rome, Italy

Collapse

Woo HG, Kim HJ, Park J, Lee J, Lee H, Kim MS, Koyanagi A, Smith L, Rahmati M, Yeo SG, Yon DK. Global burden of vaccine-associated multiple sclerosis, 1967-2022: A comprehensive analysis of the international pharmacovigilance database. J Med Virol 2024;96:e29591. [PMID: 38572940 DOI: 10.1002/jmv.29591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2024] [Revised: 03/13/2024] [Accepted: 03/25/2024] [Indexed: 04/05/2024]

Abstract

Vaccine-associated multiple sclerosis (MS) is rare, with insufficient evidence from case reports. Given the scarcity of large-scale data investigating the association between vaccine administration and adverse events, we investigated the global burden of vaccine-associated MS and potential related vaccines from 1967 to 2022. Reports on vaccine-associated MS between 1967 and 2022 were obtained from the World Health Organization International Pharmacovigilance Database (total number of reports = 120 715 116). We evaluated global reports, reporting odds ratio (ROR), and information components (IC) to investigate associations between 19 vaccines and vaccine-associated MS across 156 countries and territories. We identified 8288 reports of vaccine-associated MS among 132 980 cases of all-cause MS. The cumulative number of reports on vaccine-associated MS gradually increased over time, with a substantial increase after 2020, owing to COVID-19 mRNA vaccine-associated MS. Vaccine-associated MS develops more frequently in males and adolescents. Nine vaccines were significantly associated with higher MS reporting, and the highest disproportional associations were observed for hepatitis B vaccines (ROR 19.82; IC025 4.18), followed by encephalitis (ROR 7.42; IC025 2.59), hepatitis A (ROR 4.46; IC025 1.95), and papillomavirus vaccines (ROR 4.45; IC025 2.01). Additionally, MS showed a significantly disproportionate signal for COVID-19 mRNA vaccines (ROR 1.55; IC025 0.52). Fatal clinical outcomes were reported in only 0.3% (21/8288) of all cases of vaccine-associated MS. Although various vaccines are potentially associated with increased risk of MS, we should be cautious about the increased risk of MS following vaccination, particularly hepatitis B and COVID-19 mRNA vaccines, and should consider the risk factors associated with vaccine-associated MS.

Collapse

Affiliation(s)

Ho Geol Woo Department of Neurology, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea
Hyeon Jin Kim Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea Department of Regulatory Science, Kyung Hee University, Seoul, South Korea
Jaeyu Park Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea Department of Regulatory Science, Kyung Hee University, Seoul, South Korea
Jinseok Lee Department of Biomedical Engineering, Kyung Hee University, Yongin, South Korea
Hayeon Lee Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea Department of Biomedical Engineering, Kyung Hee University, Yongin, South Korea
Min Seo Kim Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
Ai Koyanagi Research and Development Unit, Parc Sanitari Sant Joan de Deu, Barcelona, Spain
Lee Smith Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK
Masoud Rahmati CEReSS-Health Service Research and Quality of Life Center, Assistance Publique-Hôpitaux de Marseille (APHM), Aix-Marseille University, Marseille, France Department of Physical Education and Sport Sciences, Faculty of Literature and Human Sciences, Lorestan University, Khoramabad, Iran Department of Physical Education and Sport Sciences, Faculty of Literature and Humanities, Vali-E-Asr University of Rafsanjan, Rafsanjan, Iran
Seung Geun Yeo Department of Otolaryngology-Head & Neck Surgery, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea
Dong Keon Yon Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea Department of Regulatory Science, Kyung Hee University, Seoul, South Korea Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea

Collapse

Clever S, Limpinsel L, Meyer zu Natrup C, Schünemann LM, Beythien G, Rosiak M, Hülskötter K, Gregor KM, Tuchel T, Kalodimou G, Freudenstein A, Kumar S, Baumgärtner W, Sutter G, Tscherne A, Volz A. Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection. Viruses 2024;16:417. [PMID: 38543782 PMCID: PMC10974247 DOI: 10.3390/v16030417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2024] [Revised: 03/05/2024] [Accepted: 03/06/2024] [Indexed: 05/23/2024] Open

Affiliation(s)

Sabrina Clever Institute of Virology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany; (S.C.); (C.M.z.N.); (L.-M.S.)
Leonard Limpinsel Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany; (L.L.); (G.K.); (A.F.); (S.K.); (G.S.); (A.T.)
Christian Meyer zu Natrup Institute of Virology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany; (S.C.); (C.M.z.N.); (L.-M.S.)
Lisa-Marie Schünemann Institute of Virology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany; (S.C.); (C.M.z.N.); (L.-M.S.)
Georg Beythien Department of Pathology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany; (G.B.); (M.R.); (K.H.); (K.M.G.); (W.B.)
Malgorzata Rosiak Department of Pathology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany; (G.B.); (M.R.); (K.H.); (K.M.G.); (W.B.)
Kirsten Hülskötter Department of Pathology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany; (G.B.); (M.R.); (K.H.); (K.M.G.); (W.B.)
Katharina Manuela Gregor Department of Pathology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany; (G.B.); (M.R.); (K.H.); (K.M.G.); (W.B.)
Tamara Tuchel Institute of Virology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany; (S.C.); (C.M.z.N.); (L.-M.S.)
Georgia Kalodimou Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany; (L.L.); (G.K.); (A.F.); (S.K.); (G.S.); (A.T.)
Astrid Freudenstein Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany; (L.L.); (G.K.); (A.F.); (S.K.); (G.S.); (A.T.)
Satendra Kumar Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany; (L.L.); (G.K.); (A.F.); (S.K.); (G.S.); (A.T.)
Wolfgang Baumgärtner Department of Pathology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany; (G.B.); (M.R.); (K.H.); (K.M.G.); (W.B.)
Gerd Sutter Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany; (L.L.); (G.K.); (A.F.); (S.K.); (G.S.); (A.T.)
Alina Tscherne Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany; (L.L.); (G.K.); (A.F.); (S.K.); (G.S.); (A.T.)
Asisa Volz Institute of Virology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany; (S.C.); (C.M.z.N.); (L.-M.S.)

Collapse

Salunkhe M, Tayade K, Priyadarshi M, Goel V, Gulati I, Garg A, Bhatia R, Srivastava MVP. Spectrum of various CNS inflammatory demyelination diseases following COVID-19 vaccinations. Acta Neurol Belg 2024;124:193-203. [PMID: 37668946 DOI: 10.1007/s13760-023-02373-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2023] [Accepted: 08/21/2023] [Indexed: 09/06/2023]

Abstract

BACKGROUND AND PURPOSE

Although rare, neurological adverse events have been reported post-COVID-19 vaccination. This study reports 16 patients diagnosed with CNS inflammatory demyelinating diseases (CNS-IDD) within 6 weeks of COVID-19 vaccine administration.

METHODOLOGY

A prospective observational study was conducted from June 2021 to May 2022. All patients were diagnosed according to the latest international guidelines with CNS-IDD within 6 weeks of COVID-19 vaccine exposure. Data regarding the demographic profile, clinical features, type of COVID-19 vaccination, radiological findings and occurrence of symptoms were noted and further analysed using descriptive statistics.

RESULTS

We reported 16 cases (median age 40 years) of CNS demyelination: fourteen occurred in temporal association with ChAdOx1-S vaccine and two in association with BBV152 vaccine. Median time duration of presenting symptoms after vaccination was 19 days (3-40 days). The most common presentation was myelitis (7/16 patients), followed by optic neuritis (6/16 patients). Demyelination events were reported after first and second dose in thirteen and five patients respectively, although two patients reported such events after both vaccine dosages. Myelin oligodendrocyte glycoprotein (MOG) IgG antibodies were positive in eight patients. Tumefactive demyelination was seen in four patients. Management included high-dose methylprednisolone, PLEX, IVIG or a combination of those, with a favourable outcome in the majority of cases.

CONCLUSION

Although a rare event, awareness regarding potential demyelinating episodes post-COVID-19 vaccination can help in early diagnosis. The presence of increased MOG-IgG antibodies with temporal association in post-COVID vaccine patients raises a possibility of an immunogenic phenomenon leading to demyelinating disorders.

Collapse

Paybast S, Jameie M, Shahbazi M, Habibi MA, Mohammadianinejad SE, Harirchian MH. New diagnosis of multiple sclerosis in the setting of recent Sinopharm COVID-19 vaccine (BBIBP-CorV) exposure: A series of clinical cases and updated review of the literature. CURRENT JOURNAL OF NEUROLOGY 2024;23:21-38. [PMID: 39431229 PMCID: PMC11489623 DOI: 10.18502/cjn.v23i1.16430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Accepted: 11/06/2023] [Indexed: 10/22/2024]

Salai G, Ljubičić Đ, Novak R, Grgurević L. Benign fasciculation syndrome and migraine aura without headache as possible adverse events after BNT162b2 mRNA vaccination: a web-based survey. Croat Med J 2023;64:430-435. [PMID: 38168524 PMCID: PMC10797237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2023] [Accepted: 12/01/2023] [Indexed: 01/05/2024] Open

Tsuzuki Wada T, Yokota K, Inayoshi F, Sakai S, Okumura N, Matsuda M, Osawa I, Araki Y, Funakubo Asanuma Y, Akiyama Y, Mimura T. New-onset Immune-mediated Necrotizing Myopathy and Trigeminal Neuropathy after SARS-CoV-2 mRNA Vaccination in a Patient with Rheumatoid Arthritis and Sjögren's Syndrome. Intern Med 2023;62:3699-3706. [PMID: 37839879 PMCID: PMC10781545 DOI: 10.2169/internalmedicine.2551-23] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Accepted: 08/30/2023] [Indexed: 10/17/2023] Open

Georganta I, Chasapi D, Smith CJ, Kopsidas K, Tatham A. Systematic review exploring the clinical features of optic neuritis after SARS-CoV infection and vaccination. BMJ Open Ophthalmol 2023;8:e001336. [PMID: 38057105 PMCID: PMC10711871 DOI: 10.1136/bmjophth-2023-001336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Accepted: 11/02/2023] [Indexed: 12/08/2023] Open

Najafi P, Hadizadeh M, Cheong JPG, Motl RW, Abdullah S, Mohafez H, Poursadeghfard M. Effects of tele-exercise training on physical and mental health and quality of life in multiple sclerosis: Do the effects differ by modality and clinical disease course? Mult Scler Relat Disord 2023;80:105129. [PMID: 37977056 DOI: 10.1016/j.msard.2023.105129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Revised: 10/01/2023] [Accepted: 11/04/2023] [Indexed: 11/19/2023]

Esechie A, Fang X, Banerjee P, Rai P, Thottempudi N. A case report of longitudinal extensive transverse myelitis: immunotherapy related adverse effect vs. COVID-19 related immunization complications. Int J Neurosci 2023;133:1120-1123. [PMID: 35369847 DOI: 10.1080/00207454.2022.2050907] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 03/01/2022] [Indexed: 01/03/2023]

Labani A, Chou S, Kaviani K, Ropero B, Russman K, Becker D. Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination. Mult Scler Relat Disord 2023;77:104865. [PMID: 37418929 DOI: 10.1016/j.msard.2023.104865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2023] [Revised: 06/13/2023] [Accepted: 06/29/2023] [Indexed: 07/09/2023]

Abstract

BACKGROUND

The coronavirus disease 2019 (COVID-19) pandemic created an urgency for an effective vaccine. The FDA approved vaccines offered by Pfizer-BioNTech (BNT162b2), ModernaTX (mRNA-1273) and Janssen/Johnson & Johnson (Ad26.COV2.S) have shown minimal side effects (SE) in general population studies. Multiple sclerosis (MS) patients were not specifically represented in the above studies. The MS community is interested in how these vaccines behave in people with MS. In this study, we compare the SE experienced by MS to that of the general population after SARS-CoV-2 vaccination and evaluate their risk of relapses or pseudo-relapses.

METHODS

A retrospective, single-site, cohort study of 250 MS patients who received the initial cycle of FDA approved SARS-CoV-2 vaccines with 151 of whom also received an additional booster dose. SE resulting immediately after COVID-19 vaccination were collected as part of the standard clinical care during patient visits.

RESULTS

Out of the studied 250 MS patients, 135 received the first and second doses of BNT162b2 with less than 1% and 4% pseudo-relapses respectively and 79 received the third BNT162b2 dose with a pseudo-relapse rate of 3%. 88 received the mRNA-1273 vaccine with a pseudo-relapse frequency of 2% and 5% after the first and second doses respectively. 70 patients had the mRNA-1273 vaccine booster with a 3% pseudo-relapse rate. 27 received the Ad26.COV2.S first dose, 2 of whom received a second Ad26.COV2.S booster dose, with no reports of MS worsening. No acute relapses were reported in our patient population. All patients experiencing pseudo-relapse symptoms returned to baseline within 96 h.

CONCLUSION

COVID-19 vaccine is safe in patients with MS. Cases of temporary worsening of MS symptoms following SARS-CoV-2 are rare. Our findings support those reported by other recent studies and the CDC recommendation for MS patients to receive the FDA-approved COVID-19 vaccines, including the boosters.

Collapse

Bakirtzis C, Konstantinidou N, Stavropoulou De Lorenzo S, Moysiadis T, Boziki MK, Grigoriadou E, Kesidou E, Theotokis P, Thireos E, Mitrou P, Grigoriadis N. COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece. J Clin Med 2023;12:5460. [PMID: 37685528 PMCID: PMC10488265 DOI: 10.3390/jcm12175460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Revised: 08/08/2023] [Accepted: 08/21/2023] [Indexed: 09/10/2023] Open

Affiliation(s)

Christos Bakirtzis Multiple Sclerosis Center, Second Department of Neurology, School of Medicine, Aristotle University of Thessaloniki, 54621 Thessaloniki, Greece; (N.K.); (S.S.D.L.); (M.-K.B.); (E.G.); (E.K.); (P.T.); (N.G.)
Natalia Konstantinidou Multiple Sclerosis Center, Second Department of Neurology, School of Medicine, Aristotle University of Thessaloniki, 54621 Thessaloniki, Greece; (N.K.); (S.S.D.L.); (M.-K.B.); (E.G.); (E.K.); (P.T.); (N.G.)
Sotiria Stavropoulou De Lorenzo Multiple Sclerosis Center, Second Department of Neurology, School of Medicine, Aristotle University of Thessaloniki, 54621 Thessaloniki, Greece; (N.K.); (S.S.D.L.); (M.-K.B.); (E.G.); (E.K.); (P.T.); (N.G.)
Theodoros Moysiadis Department of Computer Science, School of Sciences and Engineering, University of Nicosia, 2417 Nicosia, Cyprus;
Marina-Kleopatra Boziki Multiple Sclerosis Center, Second Department of Neurology, School of Medicine, Aristotle University of Thessaloniki, 54621 Thessaloniki, Greece; (N.K.); (S.S.D.L.); (M.-K.B.); (E.G.); (E.K.); (P.T.); (N.G.)
Eleni Grigoriadou Multiple Sclerosis Center, Second Department of Neurology, School of Medicine, Aristotle University of Thessaloniki, 54621 Thessaloniki, Greece; (N.K.); (S.S.D.L.); (M.-K.B.); (E.G.); (E.K.); (P.T.); (N.G.)
Evangelia Kesidou Multiple Sclerosis Center, Second Department of Neurology, School of Medicine, Aristotle University of Thessaloniki, 54621 Thessaloniki, Greece; (N.K.); (S.S.D.L.); (M.-K.B.); (E.G.); (E.K.); (P.T.); (N.G.)
Paschalis Theotokis Multiple Sclerosis Center, Second Department of Neurology, School of Medicine, Aristotle University of Thessaloniki, 54621 Thessaloniki, Greece; (N.K.); (S.S.D.L.); (M.-K.B.); (E.G.); (E.K.); (P.T.); (N.G.)
Eleftherios Thireos Primary Health Center of Vari, National Health System of Greece, 16672 Athens, Greece;
Panagiota Mitrou Independent Department of Therapeutic Protocols and Patient Registers, Hellenic Ministry of Health, 10433 Athens, Greece;
Nikolaos Grigoriadis Multiple Sclerosis Center, Second Department of Neurology, School of Medicine, Aristotle University of Thessaloniki, 54621 Thessaloniki, Greece; (N.K.); (S.S.D.L.); (M.-K.B.); (E.G.); (E.K.); (P.T.); (N.G.)

Collapse

Tavazzi E, Pichiecchio A, Colombo E, Rigoni E, Asteggiano C, Vegezzi E, Masi F, Greco G, Bastianello S, Bergamaschi R. The Potential Role of SARS-CoV-2 Infection and Vaccines in Multiple Sclerosis Onset and Reactivation: A Case Series and Literature Review. Viruses 2023;15:1569. [PMID: 37515255 PMCID: PMC10385211 DOI: 10.3390/v15071569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Revised: 07/07/2023] [Accepted: 07/08/2023] [Indexed: 07/30/2023] Open

Ghaderi S, Mohammadi S, Heidari M, Sharif Jalali SS, Mohammadi M. Post-COVID-19 Vaccination CNS Magnetic Resonance Imaging Findings: A Systematic Review. THE CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY = JOURNAL CANADIEN DES MALADIES INFECTIEUSES ET DE LA MICROBIOLOGIE MEDICALE 2023;2023:1570830. [PMID: 37427078 PMCID: PMC10325882 DOI: 10.1155/2023/1570830] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Revised: 04/18/2023] [Accepted: 06/23/2023] [Indexed: 07/11/2023]

Abstract

Objective

This systematic review aims to synthesize and analyze the available literature on central nervous system (CNS) magnetic resonance imaging (MRI) findings in individuals who have received COVID-19 vaccinations. Our objective is to enhance understanding of potential neurological side effects, inform clinical practice, and guide future research on the neurological implications of COVID-19 vaccination.

Methods

In this systematic review, we conducted a comprehensive search in PubMed, Scopus, and Web of Science from January 2020 to April 2023, using terms related to COVID-19 vaccination and CNS MRI findings. We evaluated the quality of the study, extracted relevant data, and included 89 eligible studies that covered various vaccines, demographics of patients, symptoms, and MRI findings to provide a thorough understanding of SARS-CoV-2 vaccination-related CNS problems.

Results

We investigated CNS MRI findings following COVID-19 vaccination across various vaccine types. Common diseases associated with post-vaccination CNS MRI findings included cerebral venous sinus thrombosis (CVST), vaccine-induced immune thrombotic thrombocytopenia (VITT), acute disseminated encephalomyelitis (ADEM), acute myelitis, autoimmune encephalitis (AE), and others. Patients presented with diverse onset symptoms and neurological manifestations. Abnormalities identified in CNS MRI findings included white matter (WM) hyperintensity. Our analysis offers a comprehensive overview of the current literature on post-vaccination CNS MRI findings. Discussion. We highlight a range of post-COVID-19 vaccination CNS MRI findings, including CVST, with a higher incidence in individuals receiving the ChAdOx1 (AstraZeneca) vaccine. Other notable observations include cases of ADEM, myelitis or transverse myelitis (TM), Guillain-Barré syndrome (GBS), and acute encephalopathy following COVID-19 vaccination. The incidence of these neurological complications is extremely rare, and the benefits of vaccination outweigh the risks. The reviewed studies were primarily case reports or case series, and thus large-scale epidemiological studies and controlled clinical trials are needed to better understand the underlying mechanisms and risk factors associated with these neurological complications following COVID-19 vaccination.

Collapse

Harel T, Gorman EF, Wallin MT. New onset or relapsing neuromyelitis optica temporally associated with SARS-CoV-2 infection and COVID-19 vaccination: a systematic review. Front Neurol 2023;14:1099758. [PMID: 37426444 PMCID: PMC10323143 DOI: 10.3389/fneur.2023.1099758] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2022] [Accepted: 05/26/2023] [Indexed: 07/11/2023] Open

Abstract

Background

Neuromyelitis optica spectrum disorder (NMOSD) is a rare chronic neuroinflammatory autoimmune condition. Since the onset of the COVID-19 pandemic, there have been reports of NMOSD clinical manifestations following both SARS-CoV-2 infections and COVID-19 vaccinations.

Objective

This study aims to systematically review the published literature of NMOSD clinical manifestations associated with SARS-CoV-2 infections and COVID-19 vaccinations.

Methods

A Boolean search of the medical literature was conducted between December 1, 2019 to September 1, 2022, utilizing Medline, Cochrane Library, Embase, Trip Database, Clinicaltrials.gov, Scopus, and Web of Science databases. Articles were collated and managed on Covidence^® software. The authors independently appraised the articles for meeting study criteria and followed PRISMA guidelines. The literature search included all case reports and case series that met study criteria and involved NMOSD following either the SARS-CoV-2 infection or the COVID-19 vaccination.

Results

A total of 702 articles were imported for screening. After removing 352 duplicates and 313 articles based on exclusion criteria, 34 articles were analyzed. A total of 41 cases were selected, including 15 patients that developed new onset NMOSD following a SARS-CoV-2 infection, 21 patients that developed de novo NMOSD following COVID-19 vaccination, 3 patients with known NMOSD that experienced a relapse following vaccination, and 2 patients with presumed Multiple Sclerosis (MS) that was unmasked as NMOSD post-vaccination. There was a female preponderance of 76% among all NMOSD cases. The median time interval between the initial SARS-CoV-2 infection symptoms and NMOSD symptom onset was 14 days (range 3-120 days) and the median interval between COVID-19 vaccination and onset of NMO symptoms was 10 days (range 1 to 97 days). Transverse myelitis was the most common neurological manifestation in all patient groups (27/41). Management encompassed acute treatments such as high dose intravenous methylprednisolone, plasmapheresis, and intravenous immunoglobulin (IVIG) and maintenance immunotherapies. The majority of patients experienced a favorable outcome with complete or partial recovery, but 3 patients died.

Conclusion

This systematic review suggests that there is an association between NMOSD and SARS-CoV-2 infections and COVID-19 vaccinations. This association requires further study using quantitative epidemiological assessments in a large population to better quantify the risk.

Collapse

Banoun H. mRNA: Vaccine or Gene Therapy? The Safety Regulatory Issues. Int J Mol Sci 2023;24:10514. [PMID: 37445690 DOI: 10.3390/ijms241310514] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2023] [Revised: 06/19/2023] [Accepted: 06/21/2023] [Indexed: 07/15/2023] Open

Yang Y, Huang L. Neurological Disorders following COVID-19 Vaccination. Vaccines (Basel) 2023;11:1114. [PMID: 37376503 PMCID: PMC10302665 DOI: 10.3390/vaccines11061114] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2023] [Revised: 06/08/2023] [Accepted: 06/14/2023] [Indexed: 06/29/2023] Open

Dinkin M, Sathi S. Neuro-Ophthalmic Visual Impairment in the Setting of COVID-19. Semin Neurol 2023. [PMID: 37311536 DOI: 10.1055/s-0043-1767715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]

Tolmacheva AS, Onvumere MK, Sedykh SE, Timofeeva AM, Nevinsky GA. Catalase Activity of IgGs of Patients Infected with SARS-CoV-2. Int J Mol Sci 2023;24:10081. [PMID: 37373231 DOI: 10.3390/ijms241210081] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Revised: 06/06/2023] [Accepted: 06/10/2023] [Indexed: 06/29/2023] Open

Ruan Z, Huan X, Su Y, Tang YL, Meng DD, Ren DL, Li CH, Hao SJ, Zhao CB, Luo SS, Li ZY, Chang T. Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study. Front Immunol 2023;14:1141983. [PMID: 37223097 PMCID: PMC10200982 DOI: 10.3389/fimmu.2023.1141983] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Accepted: 04/18/2023] [Indexed: 05/25/2023] Open

Pratap Shankar KM, Pratibha PN, Saritha V. Ayurvedic management of neurological deficits post COVID-19 vaccination - A report of two cases. J Ayurveda Integr Med 2023;14:100737. [PMID: 37343418 PMCID: PMC10247886 DOI: 10.1016/j.jaim.2023.100737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2022] [Revised: 05/23/2023] [Accepted: 05/30/2023] [Indexed: 06/23/2023] Open

Silva PBR, Silva GD. Risk and characteristics of attacks occurring after vaccination in patients with neuromyelitis optica spectrum disorders: A systematic review and meta-analysis. Mult Scler Relat Disord 2023;75:104741. [PMID: 37182477 DOI: 10.1016/j.msard.2023.104741] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Revised: 03/25/2023] [Accepted: 04/30/2023] [Indexed: 05/16/2023]

Boruah AP, Heydari K, Wapniarski AE, Caldwell M, Thakur KT. Neurological Considerations with COVID-19 Vaccinations. Semin Neurol 2023. [PMID: 37094803 DOI: 10.1055/s-0043-1767725] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/26/2023]

Jeon YH, Choi S, Park JH, Lee JK, Yeo NS, Lee S, Suh YL. Sudden Death Associated With Possible Flare-Ups of Multiple Sclerosis After COVID-19 Vaccination and Infection: A Case Report and Literature Review. J Korean Med Sci 2023;38:e78. [PMID: 36918031 PMCID: PMC10010908 DOI: 10.3346/jkms.2023.38.e78] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Accepted: 11/30/2022] [Indexed: 03/06/2023] Open

Abstract

We present an autopsy case of a 19-year-old man with a history of epilepsy whose unwitnessed sudden death occurred unexpectedly in the night. About 4 years before death, he was diagnosed with unilateral optic neuritis (ON). Demyelinating disease was suspected, but he was lost to follow up after the recovery. Six months before death, he received a second dose of mRNA coronavirus disease 2019 (COVID-19) vaccine. Three months before death, he experienced epileptic seizures for the first time. Seventeen days before death, he was infected with COVID-19, which showed self-limited course under home isolation. Several days before death, he complained of seizures again at night. Autopsy revealed multifocal gray-tan discoloration in the cerebrum. Histologically, the lesions consisted of active and inactive demyelinated plaques in the perivenous area of the white matter. Perivascular lymphocytic infiltration and microglial cell proliferation were observed in both white matter and cortex. The other major organs including heart and lung were unremarkable. Based on the antemortem history and postmortem findings, the cause of death was determined to be multiple sclerosis with suspected exacerbation. The direct or indirect involvement of cortex and deep gray matter by exacerbated multiple sclerosis may explain the occurrence of seizures. Considering the absence of other structural abnormalities except the inflammatory demyelination of the cerebrum, fatal arrhythmia or laryngospasm in the terminal epileptic seizure may explain his sudden unexpected death in the benign circumstances. In this case, the onset of seizure was preceded by COVID-19 vaccination, and the exacerbation of seizure was preceded by COVID-19 infection, respectively. Literature reporting first manifestation or relapse of multiple sclerosis temporally associated with COVID-19 vaccination or infection are reviewed.

Collapse

Acute and Chronic Demyelinating Neuropathies After COVID-19 Vaccination: A Report of 4 Cases. J Clin Neuromuscul Dis 2023;24:147-156. [PMID: 36809202 DOI: 10.1097/cnd.0000000000000418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]

Choi SY, Choi JH, Oh EH, Choi KD. Sequential orbital apex syndrome following the COVID-19 vaccination: A case report. eNeurologicalSci 2023;30:100447. [PMID: 36743268 PMCID: PMC9883071 DOI: 10.1016/j.ensci.2023.100447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2022] [Revised: 01/17/2023] [Accepted: 01/24/2023] [Indexed: 01/30/2023] Open

Álvaro-Gracia JM, Sanchez-Piedra C, Culqui D, Rosello R, Garcia-Dorta A, Campos C, Manrique-Arija S, Ruiz-Montesinos D, Ros-Vilamajo I, Rodríguez-Lozano C, Freire-González M, Caliz R, Bohorquez C, Mateo Soria L, Busquets N, Castrejon I, Sánchez-Alonso F, González-Dávila E, Diaz-Gonzalez F. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study. RMD Open 2023;9:rmdopen-2022-002936. [PMID: 36927849 PMCID: PMC10030283 DOI: 10.1136/rmdopen-2022-002936] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Accepted: 02/09/2023] [Indexed: 03/18/2023] Open

Abstract

OBJECTIVE

To investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under targeted therapies.

PATIENTS AND METHODS

1765 vaccinated patients COVID-19, 1178 (66.7%) with RA and 587 (33.3%) with PsA from the COVID-19 registry in patients with rheumatic diseases (COVIDSER) project, were included. Demographics, disease characteristics, Disease Activity Score in 28 joints (DAS28) and targeted treatments were collected. DAS28-based flare rates and categorised disease activity distribution prevaccination and post vaccination were analysed by log-linear regression and contingency analyses, respectively. The influence of vaccination on DAS28 variation as a continuous measure was evaluated using a random coefficient model.

RESULTS

The distribution of categorised disease activity and flare rates was not significantly modified by vaccination. Log-linear regression showed no significant changes in the rate of flares in the 6-month period after vaccination compared with the same period prior to vaccination in neither patients with RA nor patients with PsA. When DAS28 variations were analysed using random coefficient models, no significant variations in disease activity were detected after vaccination for both groups of patients. However, patients with RA treated with Janus kinase inhibitors (JAK-i) (1) and interleukin-6 inhibitor (IL-6-i) experienced a worsening of disease activity (1.436±0.531, p=0.007, and 1.201±0.550, p=0.029, respectively) in comparison with those treated with tumour necrosis factor inhibitor (TNF-i). Similarly, patients with PsA treated with interleukin-12/23 inhibitor (IL-12/23-i) showed a worsening of disease activity (4.476±1.906, p=0.019) compared with those treated with TNF-i.

CONCLUSION

COVID-19 vaccination was not associated with increased rate of flares in patients with RA and PsA. However, a potential increase in disease activity in patients with RA treated with JAK-i and IL-6-i and in patients with PsA treated with IL-12/23-i warrants further investigation.

Collapse

Affiliation(s)

José M Álvaro-Gracia Rheumatology Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain
Carlos Sanchez-Piedra Spanish Agency of Health Technology Assessment, Instituto de Salud Carlos III, Madrid, Spain
Dante Culqui Research Unit, Spanish Society of Rheumatology, Madrid, Spain
Rosa Rosello Rheumatology Department, Hospital General San Jorge, Huesca, Spain
Alicia Garcia-Dorta Rheumatology Department, Hospital Universitario de Canarias, La Laguna, Spain
Cristina Campos Rheumatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain
Sara Manrique-Arija Rheumatology Department, Hospital Regional Universitario de Málaga, Malaga, Spain
Dolores Ruiz-Montesinos Rheumatology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain
Inmaculada Ros-Vilamajo Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain
Carlos Rodríguez-Lozano Rheumatology Department, Hospital Universitario Insulsar Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain
Mercedes Freire-González Rheumatology, Complejo Hospitalario Universitario A Coruña Biblioteca, A Coruna, Spain
Rafael Caliz Rheumatology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain
Cristina Bohorquez Rheumatology, Hospital Universitario Príncipe de Asturias, Alcala de Henares, Spain
Lourdes Mateo Soria Rheumatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Noemí Busquets Rheumatology Department, Hospital General de Granollers, Granollers, Spain
Isabel Castrejon Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain Research Unit, Instituto de Investigacion Sanitaria Gregorio Maranon, Madrid, Spain
Fernando Sánchez-Alonso Research Unit, Spanish Society of Rheumatology, Madrid, Spain
Enrique González-Dávila Departamento de Estadística e Investigación Operativa, Universidad de La Laguna, La Laguna, Spain
Federico Diaz-Gonzalez Rheumatology Department, Hospital Universitario de Canarias, La Laguna, Spain Department of Internal Medicine, Dermatology and Psychiatry, Universidad de La Laguna, La Laguna, Spain

Collapse

A rare case of a wall-eyed bilateral internuclear ophthalmoplegia (WEBINO) syndrome in a patient with cutaneous lupus erythematosus after COVID-19 infection. J Neurol 2023;270:1224-1228. [PMID: 36576573 PMCID: PMC9795426 DOI: 10.1007/s00415-022-11548-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2022] [Revised: 12/22/2022] [Accepted: 12/23/2022] [Indexed: 12/29/2022]

Hosseini R, Askari N. A review of neurological side effects of COVID-19 vaccination. Eur J Med Res 2023;28:102. [PMID: 36841774 PMCID: PMC9959958 DOI: 10.1186/s40001-023-00992-0] [Citation(s) in RCA: 33] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2022] [Accepted: 01/04/2023] [Indexed: 02/27/2023] Open

Lee S, Muccilli A, Schneider R, Selchen D, Krysko KM. Acute central nervous system inflammation following COVID-19 vaccination: An observational cohort study. Mult Scler 2023;29:595-605. [PMID: 36840605 PMCID: PMC9969223 DOI: 10.1177/13524585231154780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]

Kim S, Seok HY. Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD. Neurol Sci 2023;44:1841-1848. [PMID: 36781562 PMCID: PMC9924883 DOI: 10.1007/s10072-023-06676-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2022] [Accepted: 02/08/2023] [Indexed: 02/15/2023]

Samim M, Dhar D, Arshad F, Anudeep D, Patel VG, Neeharika SR, Dhamija K, Ravindranath CM, Yadav R, Raja P, Netravathi M, Menon D, Holla VV, Kamble NL, Pal PK, Nalini A, Vengalil S. Co-VAN study: COVID-19 vaccine associated neurological diseases- an experience from an apex neurosciences centre and review of the literature. J Clin Neurosci 2023;108:37-75. [PMID: 36586226 PMCID: PMC9780646 DOI: 10.1016/j.jocn.2022.12.015] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Revised: 11/19/2022] [Accepted: 12/19/2022] [Indexed: 12/25/2022]

Abstract

BACKGROUND

Recent studies have shown various neurological adverse events associated with COVID-19 vaccine.

OBJECTIVE

We aimed to retrospectively review and report the neurological diseases temporally associated with COVID-19 vaccine.

METHODS

We performed a retrospective chart review of admitted patients from 1st February 2021 to 30th June 2022. A total of 4672 medical records were reviewed of which 51 cases were identified to have neurological illness temporally associated with COVID-19 vaccination.

RESULTS

Out of 51 cases, 48 had probable association with COVID-19 vaccination while three had possible association. Neurological spectrum included CNS demyelination (n = 39, 76.5 %), Guillain-Barré-syndrome (n = 3, 5.9 %), stroke (n = 6, 11.8 %), encephalitis (n = 2, 3.9 %) and myositis (n = 1, 2.0 %). Female gender had a greater predisposition (F:M, 1.13:1). Neurological events were more commonly encountered after the first-dose (n = 37, 72.5%). The mean latency to onset of symptoms was 13.2 ± 10.7 days after the last dose of vaccination. COVIShield (ChAdOx1) was the most commonly administered vaccine (n = 43, 84.3 %). Majority of the cases with demyelination were seronegative (n = 23, 59.0 %) which was followed by anti-Myelin oligodendrocyte-glycoprotein associated demyelination (MOGAD) (n = 11, 28.2 %) and Neuromyelitis optica (NMOSD) (n = 5, 12.8 %). Out of 6 Stroke cases, 2 cases (33.3 %) had thrombocytopenia and coagulopathy. At discharge, 25/51 (49.0 %) of the cases had favourable outcome (mRS 0 to 1). Among six patients of stroke, only one of them had favourable outcome.

CONCLUSION

In this series, we describe the wide variety of neurological syndromes temporally associated with COVID-19 vaccination. Further studies with larger sample size and longer duration of follow-up are needed to prove or disprove causality association of these syndromes with COVID-19 vaccination.

Collapse

Moezinia C, Harbinson EB, Maweni RM. Concurrent facial and trigeminal nerve palsies in a child following COVID-19 vaccination with the Pfizer vaccine. BMJ Case Rep 2023;16:16/1/e253302. [PMID: 36717162 PMCID: PMC9887692 DOI: 10.1136/bcr-2022-253302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open

Ebrahimi N, Mazdak M, Shaygannejad V, Mirmosayyeb O. CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series. Vaccine 2023;41:1003-1008. [PMID: 36635139 PMCID: PMC9816077 DOI: 10.1016/j.vaccine.2023.01.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2022] [Revised: 08/28/2022] [Accepted: 01/03/2023] [Indexed: 01/09/2023]

Mirmosayyeb O, Ghaffary E, Vaheb S, Pourkazemi R, Shaygannejad V. Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccines: A systematic review. Rev Neurol (Paris) 2023;179:265-281. [PMID: 36658048 PMCID: PMC9844421 DOI: 10.1016/j.neurol.2022.11.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Revised: 11/01/2022] [Accepted: 11/14/2022] [Indexed: 01/19/2023]

Hromić-Jahjefendić A, Barh D, Uversky V, Aljabali AA, Tambuwala MM, Alzahrani KJ, Alzahrani FM, Alshammeri S, Lundstrom K. Can COVID-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading to? Vaccines (Basel) 2023;11:vaccines11020208. [PMID: 36851087 PMCID: PMC9960675 DOI: 10.3390/vaccines11020208] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Revised: 01/05/2023] [Accepted: 01/13/2023] [Indexed: 01/20/2023] Open

Capone F, Rossi M, Cruciani A, Motolese F, Pilato F, Di Lazzaro V. Safety, immunogenicity, efficacy, and acceptability of COVID-19 vaccination in people with multiple sclerosis: a narrative review. Neural Regen Res 2023;18:284-288. [PMID: 35900404 PMCID: PMC9396498 DOI: 10.4103/1673-5374.346539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open

Natung T, Singh T, Devi O, Pandey I. A rare case of bilateral optic neuritis post-Covishield (ChAdOx1-S [recombinant]) vaccination. Oman J Ophthalmol 2023;16:157-160. [PMID: 37007264 PMCID: PMC10062071 DOI: 10.4103/ojo.ojo_31_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Revised: 07/08/2022] [Accepted: 11/19/2022] [Indexed: 02/25/2023] Open

Wang S, Lv J, He C, Yang Y, Zheng Y, Ye L, Chen C, Shen C, Xu S, Ding Y, Guo Y, Tang Y, Wang S, Ding M. COVID-19 vaccination hesitancy and safety among adult people with epilepsy in eastern China. Epilepsy Behav 2023;138:108984. [PMID: 36423385 PMCID: PMC9637523 DOI: 10.1016/j.yebeh.2022.108984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2022] [Revised: 10/28/2022] [Accepted: 10/29/2022] [Indexed: 11/09/2022]

Affiliation(s)

Shan Wang Epilepsy Center, Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Jin Lv Epilepsy Center, Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Chenmin He Epilepsy Center, Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Yuyu Yang Epilepsy Center, Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Yuanyuan Zheng Epilepsy Center, Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Lingqi Ye Epilepsy Center, Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Cong Chen Epilepsy Center, Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Chunhong Shen Epilepsy Center, Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Sha Xu Epilepsy Center, Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Yao Ding Epilepsy Center, Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Yi Guo Epilepsy Center, Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Yelei Tang Epilepsy Center, Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Shuang Wang Epilepsy Center, Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Meiping Ding Epilepsy Center, Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Collapse

Harahsheh E, Callister M, Hasan S, Gritsch D, Valencia-Sanchez C. Aquaporin-4 IgG neuromyelitis optica spectrum disorder onset after Covid-19 vaccination: Systematic review. J Neuroimmunol 2022;373:577994. [PMID: 36332464 DOI: 10.1016/j.jneuroim.2022.577994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2022] [Revised: 10/14/2022] [Accepted: 10/24/2022] [Indexed: 11/29/2022]

Rinaldi V, Bellucci G, Buscarinu MC, Reniè R, Marrone A, Nasello M, Zancan V, Nistri R, Palumbo R, Salerno A, Salvetti M, Ristori G. CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic review. Front Neurol 2022;13:1018785. [PMID: 36530641 PMCID: PMC9752005 DOI: 10.3389/fneur.2022.1018785] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2022] [Accepted: 10/31/2022] [Indexed: 07/30/2023] Open

Abstract

BACKGROUND

Vaccinations provided the most effective tool to fight the SARS-CoV-2 pandemic. It is now well established that COVID-19 vaccines are safe for the general population; however, some cases of rare adverse events following immunization have been described, including CNS Inflammatory Demyelinating Events (CIDEs). Although observational studies are showing that these events are rare and vaccines' benefits highly outweigh the risks, collecting and characterizing post-COVID-19 vaccine CIDEs might be relevant to single out potential risk factors and suggest possible underlying mechanisms.

METHODS

Here we describe six CIDEs, including two acute transverse myelitis (ATM), three multiple sclerosis (MS), and one neuromyelitis optica spectrum disorder (NMOSD), occurring between 8 and 35 days from a COVID-19 vaccine. Moreover, we performed a systematic literature search of post-COVID-19 vaccines CIDEs, including ATM, ADEM, MS, and NMOSD/MOGAD, published worldwide between December 2020 and December 2021, during 1 year of the vaccination campaign. Clinical/MRI and CSF/serum characteristics were extracted from reviewed studies and pooled-analyzed.

RESULTS

Forty-nine studies were included in the systematic review, reporting a total amount of 85 CIDEs. Considering our additional six cases, 91 CIDEs were summarized, including 24 ATM, 11 ADEM, 47 MS, and nine NMOSD/MOGAD. Overall, CIDEs occurred after both mRNA (n = 46), adenoviral-vectored (n = 37), and inactivated vaccines (n = 8). Adenoviral-vectored vaccines accounted for the majority of ADEM (55%) and NMOSD/MOGAD (56%), while mRNA vaccines were more frequent in MS new diagnoses (87%) and relapses (56%). Age was heterogeneous (19-88) and the female sex was prevalent. Time from vaccine to symptoms onset was notably variable: ADEM and NMOSD/MOGAD had a longer median time of onset (12.5 and 10 days) compared to ATM and MS (6 and 7 days) and further timing differences were observed between events following different vaccine types, with ATM and MS after mRNA-vaccines occurring earlier than those following adenoviral-vectored ones.

CONCLUSION

Both the prevalence of vaccine types for certain CIDEs and the heterogeneity in time of onset suggest that different mechanisms-with distinct dynamic/kinetic-might underly these events. While epidemiological studies have assessed the safety of COVID-19 vaccines, descriptions and pooled analyses of sporadic cases may still be valuable to gain insights into CIDE's pathophysiology.

Collapse